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PNTRODUCTION
Regulation of immune reactions is critical in
ealth and disease. Nowhere is this clearer than fol-
owing allogeneic hematopoietic cell transplantation
HCT). Here the beneﬁcial effects of graft-versus-
umor reactions are clearly demonstrated, as well as
he detrimental morbidity and mortality of uncon-
rolled graft-versus-host disease (GVHD). Control of
mmune reactions is complex and involves many fac-
ors including blood ﬂow, micro-environmental inter-
ctions, cytokines, chemokines and both pro-inﬂam-
atory and anti-inﬂammatory molecules. In addition
t has become well recognized that specialized popu-
ations of cells, termed regulatory T cells, are critically
nvolved in controlling immune reactions. Although
he ﬁeld of regulatory T cell biology has been ex-
lored for many years, the more recent identiﬁcation
f speciﬁc populations of cells capable of regulating
mmune responses with deﬁned phenotype has opened
ur re-examination of the potential impact of these
ellular populations on immune function. To date, a
umber of different cell populations have been char-
cterized with deﬁned ability to regulate immune re-
ctions, which include two major cell populations,
amely those of CD4CD25 regulatory T cells
Treg) [1] and abTCR
 NK-T cells which express an
nvariant T cell receptor and are CD1 reactive [2].
hese cellular populations have generated enormous
nterest in the ﬁeld of HCT since animal models have
emonstrated the potential beneﬁt of regulatory T
ell biology.
OLES OF REGULATORY T CELLS IN
LLOGENEIC HCT
Numerous studies have demonstrated the poten-
ial beneﬁt of regulatory T cells in the setting of
llogeneic HCT [3-5]. These studies are best demon-
trated by the adoptive transfer of deﬁned numbers of
reg in the inoculum of cells administered in the
etting of allogeneic HCT. Several groups have dem-
nstrated that a 1:1 ratio of conventional CD4 and
D8 cells (Tcon) with Treg results in control of
VHD. This has been demonstrated across multiple c
2ouse strains demonstrating that Treg are capable of
ontrolling GVHD. Several studies have also demon-
trated that in these experimental settings, that adjust-
ng the ratio of Treg:Tcon results in maintenance of
VT responses [6-8]. The proposed mechanism of
his observation is that the Treg control the alloreac-
ive expansion of Tcon but not their activation. The
assive expansion of Tcon is required for the disease
rocess of GVHD whereas activation is more required
or GVT. Therefore, by controlling the proliferation
f alloreactive T cells, the clinical sequelae of GVHD
an be controlled. Additional studies have demon-
trated that Treg likely perform these functions in
peciﬁc microenvironments since the speciﬁc lym-
hoid homing molecule CD62L is critically important
n Treg function [9,10]. Interestingly, both CD62L

nd CD62L Treg are capable of controlling the
ixed lymphocyte reaction in vitro. These studies
emonstrate the importance of in vivo studies to assess
reg function which are quite accessible in murine
odels, however, extremely difﬁcult in the clinic. The
nly in vitro functional assay which has been estab-
ished for Treg is their ability to suppress the mixed
ymphocyte reaction (MLR) which is a useful but
omewhat limited assay of Treg function. T cell invari-
nt NK-T cells upon activation through CD1 [11]
roduce high levels of IL-4 which has been demon-
trated to be critically important in their biological
unction of controlling immune reactions [2]. In this
etting, the ratio of regulatory to invariant TCR
K-T cells has resulted in altering the environment
uch that these animals are markedly resistant to de-
eloping GVHD [12]. These strategies have been well
stablished in murine models and reproduced by a
umber of different laboratories. The clinical transla-
ion of an approach to alter the ratio of Tcon to NK-T
ells developed in murine models has resulted in a
arkedly low risk of acute GVHD [13]. For the re-
ainder of this review we will focus on Treg pheno-
ype and function.
HENOTYPE
Regulatory T cells have been characterized by the
ell surface phenotype of CD4CD25, however, to
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Regulatory T Cells 13ate there is no unique repertoire of cell surface
olecules which unambiguously deﬁnes regulatory
cells. Of the CD4CD25 Treg, the CD25 high
r bright population is clearly the population with
ost Treg function. Identiﬁcation of the expression
f the Foxp3 transcription factor which is tightly
orrelated with Treg function has been critically
mportant in deﬁning those populations of cells
hich are biologically active [1,14,15]. In numerous
tudies, the CD4CD25 high cells express Foxp3,
hereas the CD4CD25 intermediate cells are a
ixed population of CD4CD25 cells and Foxp3
xpressing cells (Figure 1). Therefore, expression of
oxp3 can also be used to identify Treg in biological
amples. However, because this molecule is an in-
racellular transcription factor, it is not possible to
se this marker for cell sorting functions. A number
f studies have demonstrated that both murine and
uman cells express Foxp3 and there is on-going
ebate as to whether Foxp3 deﬁnes all the Treg

opulations or is merely a marker for a predominant
reg population [16,17]. In addition, recent studies
ave indicated that CD127 (IL-7 receptor) better
eﬁnes the CD4CD25 Treg [18,19]. Therefore,
ells with the phenotype of CD4CD25 IL-7 re-
eptor negative deﬁnes the majority of cells in the
opulation which express Foxp3 and have Treg func-
ion. These phenotypic markers are critically im-
Figuortant to isolate cells to utilize in clinical studies. whis population is rare accounting for 5-10% of
he CD4 cells and 1-4% of all T cells in the
eripheral blood.
SOLATION
The ability to isolate Treg is dependent upon a
ariety of different techniques. Since these cells are
relatively rare cell population, it is difﬁcult to use
ell sorting as the exclusive technique. A variety of
roups have used magnetic bead separation for iso-
ation of CD25 cells. This results in signiﬁcant
nrichment of the CD4CD25 Treg cells, how-
ver, in these preparations, they remain only 50%
oxp3. However, for other applications where a
uriﬁed population of Treg is required, additional
pproaches may be necessary. One approach is to
ort the CD25 high positive population, however,
his has been associated with signiﬁcant loss of
oxp3 cells. As discussed above, the use of the
D127 or IL-7 receptor appears to be an improved
pproach whereby cells that are IL-7 receptor neg-
tive but CD4CD25 can be isolated by cell sort-
ng techniques. In our hands, this represents the
ajority of Foxp3 expressing regulatory T cells and
lso results in isolating the majority of Foxp3 cells
●●ithin an apheresis sample.
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Negrin and Hou14X VIVO EXPANSION
A number of groups have demonstrated that T
ells, including Treg, can be expanded by ex vivo cul-
ure techniques [20,21]. Several different approaches
ave been utilized involving stimulation with anti-
D3 to activate T cell receptor and co-stimulation
hrough CD28. TGF may also play an important
ole and IL-2 is absolutely required for Treg expansion
5]. Other groups have used dendritic cell activation in
hese cultures to expand the Treg population. In some
tudies, expansion of up to 1,000-fold can be achieved
ver several weeks [21]. Of speciﬁc concern is that
onventional T cells also rapidly expand under these
ulture conditions such that if the input cells are not
ighly puriﬁed for Treg that these cultures may be
vergrown by conventional CD4 and CD8 cells using
D3xCD28 beads and IL-2. Several approaches can
e performed to overcome this limitation. These in-
lude the use of highly puriﬁed input cells with
D127CD4CD25 cells, by the addition of rapa-
ycin which appears to control the expansion of con-
entional T cells preferentially over regulatory T cells
22] or through the isolation of CD45RA cells prior
o expansion [23].
VIDENCE THAT REGULATORY T CELLS ARE
MPORTANT IN HUMAN HEMATOPOIETIC
ELL TRANSPLANTATION
A number of studies have been performed by mea-
uring Treg in GVHD development by characterizing
he content of Treg in the peripheral blood of patients
ho have undergone allogeneic HCT. These studies
ave resulted in mixed results in that early studies
omewhat paradoxically reported a higher frequency
f CD25 high positive T cells were associated with a
igher incidence of acute and chronic GVHD [24]. In
ddition, a second study showed that CD25bright T cell
ontent in the peripheral blood of patients 100 days
ollowing transplantation was associated with a higher
isk of graft-versus-host disease. However, it is impor-
ant to note that upon activation conventional CD4
ells also express CD25 so it is difﬁcult, if not impos-
ible, to differentiate between activated T cells and
egulatory T cells.
More recent retrospective analyses have incorpo-
ated Foxp3 expression along with cell phenotype.
everal studies have shown a decrease in Foxp3 levels
n the peripheral blood of patients with both acute and
hronic GVHD [25]. In one study the level of Foxp3
xpression assessed by quantitative PCR correlated
nversely with the incidence of chronic GVHD and
ncreased as GVHD resolved [26]. In addition, a re-
ent study demonstrated that the Treg content of the
raft correlated with acute GVHD such that those
atients with higher numbers of Treg had lower risk of tcute GVHD as analyzed by phenotypic analysis and
oxp3 expression [27].
In summary, although there are somewhat mixed
esults in correlating the numbers of Foxp3 expressing
ells, several studies have been supportive of the con-
ept that higher numbers of Treg may correlate with
ower GVHD risk although additional larger cohorts
f patients are likely necessary for deﬁnitive conclu-
ions. It should also be noted that in almost all of the
urine studies Treg function is in tissues, either in
odal sites or in the peripheral tissues, yet in humans
here is little access to these tissues for analysis.
herefore, the analysis of peripheral blood has some
otential ﬂaws and caveats which are difﬁcult to con-
rol for in clearly articulating the role of Treg in
uman GVHD pathophysiology.
LINICAL APPLICATION
Due to the profound effects of Treg on GVHD
athophysiology in murine models, their potential
ole in the clinic seems obvious. A major limitation to
eveloping Treg is the relative paucity of these cell
opulations in the peripheral blood or bone marrow
amples of donors or patients undergoing HCT.
learly technical advances are required to isolate suf-
cient numbers of Treg which, as discussed above, can
e isolated by magnetic bead selection and/or cell
orting techniques. In addition expansion of Treg may
e necessary in some clinical situations to obtain suf-
cient numbers of cells. Nonetheless, a number of
roups are exploring the clinical application of Treg in
he clinic. One approach has been to use magnetic
ead separation to enrich for Treg such that the ratio
s roughly 1:1 with conventional CD4CD25 cells.
his approach is under exploration by Edinger, et al.
n a safety trial with early demonstration that this is
echnically feasible and is well tolerated. Additional
tudies are proposed, for example in the haplo-iden-
ical setting, where adjusting the mixture of Treg with
con may result in control of GVHD and possibly
mprove GVL effects, as well as enhance immune
econstitution. One concern is that there is emerging
vidence that different immunosuppressive medica-
ions may have profoundly different effects on Treg
unction [28]. Because of these issues it is important
hat different clinical approaches be explored by sev-
ral different groups in an effort to translate the ﬁnd-
ngs of Treg biology into the clinic.
In summary, the explosion of information on the
unction of regulatory T cells and biological similari-
ies between human and murine cells has made clinical
pplication attractive. In allogeneic HCT, the goal
ill be to determine whether Treg are capable of
ontrolling GVHD reactions while allowing for main-
enance of GVT. The clinical translation is challeng-
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Regulatory T Cells 15ng due to the relative paucity of these cells. We look
orward to future clinical trials exploring this exciting
opulation of regulatory T cells in the transplant set-
ing.
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